Login / Signup

Use of Cinacalcet for the Management of Primary Hyperparathyroidism in Pregnancy.

Elissa FosterNaim M Maalouf
Published in: JCEM case reports (2024)
Primary hyperparathyroidism in pregnancy is uncommon. Consequently, there are no randomized controlled studies that address treatment of primary hyperparathyroidism in pregnancy, and the efficacy and safety of medical management with cinacalcet in this setting is unknown. We report a case of a 28-year-old woman with primary hyperparathyroidism and hypercalcemia that worsened during her third trimester of pregnancy. Cinacalcet led to achievement of normocalcemia, allowing the delay of parathyroidectomy until after delivery of the baby. We also review the published literature on cinacalcet use in the management of primary hyperparathyroidism during pregnancy. Cinacalcet is typically reserved for pregnant patients with severe and symptomatic hypercalcemia, primarily serving as a last resort to delay parathyroidectomy until either the second trimester or the postpartum period.
Keyphrases
  • preterm birth
  • pregnancy outcomes
  • healthcare
  • pregnant women
  • systematic review
  • randomized controlled trial
  • clinical trial
  • open label
  • gestational age
  • phase iii